Company / R&D per Share
Dexcom R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$1.56
FY2025
5-year range
$0.93 / $5.38
FY2021-FY2025
Trend
+10.1%
vs FY2024
Sector context
#60 of 108
Health Care
What the data says
At $1.56, Dexcom's r&d per share ranks #60 of 108 in the Health Care sector. R&D per Share has increased for 3 consecutive years, from $0.93 in FY2022 to $1.56 in FY2025.
Based on SEC 10-K filings.
1.56 in FY2025 with a 5-year CAGR of -16.1%.
Improved from $1.31 to $1.56 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +18.8%
- 5-Year CAGR
- -16.1%
- 10-Year CAGR
- -
Sector benchmark
#60 of 108 in Health CareTop 56% of 108This company $1.56 Sector average $2.07
▼
-24.8% below sector average
Key checks
Key Insights
- Dexcom's r&d per share has grown for 3 consecutive years.
- In FY2025, r&d per share increased 10.1% year-over-year.
- Ranks #60 out of 108 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2021.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
- Strong return on equity: 26.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.56 | +10.1% |
| FY2024 | $1.41 | +7.7% |
| FY2023 | $1.31 | +41.5% |
| FY2022 | $0.93 | -82.8% |
| FY2021 | $5.38 | +43.7% |
| FY2020 | $3.75 | +25.4% |
| FY2019 | $2.99 | +30.1% |
| FY2018 | $2.30 | +41.2% |
| FY2017 | $1.63 | +91.3% |
| FY2016 | $0.85 | +46.6% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026